Skip to main content
TipRanks
Go Ultimate75% OFF

Illumina (ILU) AI Stock Analysis

1 Followers
CH:ILU

Illumina

(BX Swiss:ILU)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Clinical Sequencing GrowthStrong clinical consumables growth indicates expanding adoption of sequencing in diagnostics and clinical trials. This market mix can provide a more durable growth engine than research demand, supporting recurring reagent revenue and improving the company’s medium-term revenue resilience.
Negative Factors
Research Market DeclinesContinued weakness in research and applied consumables weighs on the company’s broad customer base and offsets clinical growth. If research budgets remain constrained, lower instrument utilization can reduce recurring reagent pull-through and limit the pace of overall revenue recovery.

Illumina Business Overview & Revenue Model

Company Description

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research...

Illumina Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|Next Earnings Date:Feb 11, 2027
Earnings Call SentimentPositive

The call was strongly positive. Illumina reported revenue, margin, EPS, cash flow, clinical demand, and NovaSeq X placements above expectations, raised full-year guidance, and highlighted expanding opportunities in clinical sequencing, multi-omics, software, and AI-based data sets. The main challenges were declines in research and applied markets, weaker instrument revenue in certain regions, ongoing pricing and cost headwinds, slower clinical conversion to the NovaSeq X, and uncertainty related to China and trade restrictions.

Positive Updates

Q3 Revenue and Earnings Exceeded Guidance
Rest-of-world organic revenue grew 5%, operating margin was 25%, which was 100 basis points above guidance, and diluted EPS was $1.44, up 7% year-over-year and above the high end of the guidance range.

Negative Updates

Research and Applied Consumables Declined
Sequencing consumables sales in research and applied markets declined 6% in rest-of-world markets in Q3. Management continued to expect mid- to high-single-digit declines for research and applied consumables in 2026, although it said research activity showed signs of stabilizing.

Company Guidance

Illumina raised fiscal-year 2026 revenue guidance by $30 million at the midpoint to $4.64 to 4.66 billion, expects rest of world organic growth greater than 5%, rest of world organic sequencing consumable growth of mid-single digits, low double-digit instrument growth, operating margins of approximately 23.6% at the high end of our previous guidance, and diluted EPS guidance of $5.40 to $5.45, representing year-over-year growth of 12% to 13%; for the fourth quarter, it expects revenue of $1.22 to 1.24 billion, rest of the world organic growth of approximately 4.5%, EPS of $1.51 to $1.56, operating margin of approximately 25%, and 5% to 6% growth in consumables overall. For 2026, it continues to expect mid-teens clinical growth and mid to high single-digit declines in research and applied sequencing consumables for rest of world, while clinical growth is expected to remain in the mid-teens; it also expects operating margins of approximately 25% in the second half of 2026, up about 400 basis points versus 2024. For 2027, management said it will provide full guidance on the fourth quarter earnings call, described high single digit in that range as the current consumables framework, and said new products and BioInsight could add one to two points of growth for 2027.

Illumina Risk Analysis

Illumina disclosed 29 risk factors in its most recent earnings report. Illumina reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Illumina Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:ILU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
QGENQGEN77Outperform$10.30B26.8211.04%5.29%2.17%-5.13%
TMOTMO77Outperform$259.44B36.8713.31%0.26%8.27%9.59%
TWSTTWST73Outperform$7.35B-53.65-23.20%―22.00%-60.49%
NTRANTRA63Neutral$46.27B-279.90-9.18%―37.43%49.82%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GHGH44Neutral$20.52B-41.22249.03%―41.69%-14.59%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%QGENTMONTRAGHTWSTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:ILU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
QGENQiagen49.896.0813.88%
TMOThermo Fisher Scientific700.22135.0523.89%
NTRANatera Inc.319.09113.0554.87%
GHGuardant Health151.7055.2257.23%
TWSTTwist Bioscience111.6085.14321.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.